Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610935 · ClinicalTrials.gov registry record · Phase 3
Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
A Phase 3 study, sponsored by BioCryst Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 82
- Enrollment target
NCT00610935: Clinical Trial Phase 3 study, sponsored by BioCryst Pharmaceuticals.
NCT00610935 is a Phase 3 study that was terminated before completion, run by BioCryst Pharmaceuticals. The registered enrollment target is 82 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00610935, a Phase 3 study, was terminated before completion, sponsored by BioCryst Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 82 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectivess of a single intramuscular injection of peramivir for the treatment of subjects with acute, uncomplicated influenza.
Primary Outcome
The primary efficacy endpoint was the time to alleviation of symptoms of influenza in subjects diagnosed with influenza, defined as the time from injection of study drug to the start of the time period when a subject had Alleviation of Symptoms. A subject had Alleviation of Symptoms if each of the seven symptoms of influenza (cough, sore throat, nasal obstruction, myalgia \[aches and pains\], headache, feverishness, and fatigue) as self-assessed and recorded in the subject diary were either abse
Interventions
- DRUG Placebo
- DRUG Peramivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Why NCT00610935 stopped before completion
NCT00610935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00610935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00610935 about?
NCT00610935 is a clinical study titled "Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza". The purpose of this study is to determine the safety and effectivess of a single intramuscular injection of peramivir for the treatment of subjects with acute, uncomplicated influenza.
What is the current status of trial NCT00610935?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 82 participants. The study started on 2008-01. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00610935?
The interventions under investigation include: Placebo (DRUG), Peramivir (DRUG).
Who is sponsoring clinical trial NCT00610935?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00610935's enrollment target sits among peer trials
82 1752nd of 2000 higher than 249 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia